Phase I clinical trial of intra-bone marrow cotransplantation of mesenchymal stem cells in cord blood transplantation. (14th December 2020)

• Record Type: Journal Article
• Authors: Goto, Tatsunori; Murata, Makoto; Nishida, Tetsuya; Terakura, Seitaro; Kamoshita, Sonoko; Ishikawa, Yuichi; Ushijima, Yoko; Adachi, Yoshiya; Suzuki, Satoshi; Kato, Katsuyoshi; Hirakawa, Akihiro; Nishiwaki, Satoshi; Nishio, Nobuhiro; Takahashi, Yoshiyuki; Kodera, Yoshihisa; Matsushita, Tadashi; Kiyoi, Hitoshi
• Is Part Of: Stem cells translational medicine. Volume 10:Number 4(2021)
• Page Start: 542
• Page End: 553
• Publication Date: 2020-12-14
• Subjects: cord blood transplantation -- engraftment -- graft-vs-host disease -- intra-bone marrow -- mesenchymal stem cell; Stem cells -- Periodicals; Regenerative medicine -- Periodicals; Periodicals; 616.0277405
• DOI: 10.1002/sctm.20-0381
• Languages: English
• ISSNs: 2157-6564

Abstract

Abstract: Mesenchymal stem cells (MSCs) have immunomodulatory properties and support hematopoiesis in the bone marrow (BM). To develop a new strategy to not only prevent graft-vs-host disease (GVHD) but also to enhance engraftment, a phase I trial of cord blood transplantation (CBT) combined with intra-BM injection of MSCs (MSC-CBT) was designed. Third-party BM-derived MSCs were injected intra-BM on the day of CBT. The conditioning regimen varied according to patient characteristics. GVHD prophylaxis was tacrolimus and methotrexate. The primary endpoint was toxicity related to intra-BM injection of MSCs. Clinical outcomes were compared with those of six controls who received CBT alone. Five adult patients received MSC-CBT, and no adverse events related to intra-BM injection of MSCs were observed. All patients achieved neutrophil, reticulocyte, and platelet recoveries, with median times to recoveries of 21, 35, and 38 days, respectively, comparable with controls. Grade II-IV acute GVHD developed in three controls but not in MSC-CBT patients. No patients developed chronic GVHD in both groups. At 1 year after transplantation, all MSC-CBT patients survived without relapse. This study shows the safety of MSC-CBT, and the findings also suggest that cotransplantation of MSCs may prevent GVHD with no inhibition of engraftment. This trial was registered at the University Hospital Medical Information Network Clinical Trials Registry as number 000024291. Abstract : Mesenchymal stem cells (MSCs), which were derived from bone marrow (BM) of third-party donor, were injected intra-BM of recipient 4 hours before cord blood transplantation (CBT). This study shows the safety of CBT combined with intra-BM injection of MSCs, and also suggests that co-transplantation of MSCs may prevent graft-vs-host disease without inhibition of engraftment.